Literature DB >> 14670917

Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants.

Georg Rauser1, Hermann Einsele, Christian Sinzger, Dorothee Wernet, Gabriele Kuntz, Mario Assenmacher, John D M Campbell, Max S Topp.   

Abstract

Adoptive transfer of cytomegalovirus (CMV)-specific T cells can restore long-lasting, virus-specific immunity and clear CMV viremia in recipients of allogeneic stem cell transplants if CD4(+) and CD8(+) CMV-specific T cells are detected in the recipient after transfer. Current protocols for generating virus-specific T cells use live virus, require leukapheresis of the donor, and are time consuming. To circumvent these limitations, a clinical-scale protocol was developed to generate CMV-specific T cells by using autologous cellular and serum components derived from a single 500-mL blood draw. CMV-specific T cells were stimulated simultaneously with CMV-specific major histocompatibility complex class I (MHC I)- restricted peptides and CMV antigen. Activated T cells were isolated with the interferon-gamma (IFN-gamma) secretion assay and expanded for 10 days. In 8 randomly selected, CMV-seropositive donors, 1.34 x 10(8) combined CD4(+) and CD8(+) CMV-specific T cells, on average, were generated, as determined by antigen-triggered IFN-gamma production. CMV-infected fibroblasts were efficiently lysed by the generated T cells, and CMV-specific CD4(+) and CD8(+) T cells expanded if they were stimulated with natural processed antigen. On the other hand, CD4(+) and CD8(+) T cell-mediated alloreactivity of generated CMV-specific T-cell lines was reduced compared with that of the starting population. In conclusion, the culture system developed allowed the rapid generation of allodepleted, highly enriched, combined CD4(+) and CD8(+) CMV-specific T cells under conditions mimicking good manufacturing practice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14670917     DOI: 10.1182/blood-2003-09-3056

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation.

Authors:  Sergio Rutella; Franco Locatelli
Journal:  Am J Transl Res       Date:  2011-09-10       Impact factor: 4.060

Review 2.  Rapid detection, enrichment and propagation of specific T cell subsets based on cytokine secretion.

Authors:  J D M Campbell; A Foerster; V Lasmanowicz; M Niemöller; A Scheffold; M Fahrendorff; G Rauser; M Assenmacher; A Richter
Journal:  Clin Exp Immunol       Date:  2010-10-21       Impact factor: 4.330

3.  Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

Authors:  Zhongde Wang; Corinna La Rosa; Zhongqi Li; Heang Ly; Aparna Krishnan; Joy Martinez; William J Britt; Don J Diamond
Journal:  Vaccine       Date:  2006-10-06       Impact factor: 3.641

Review 4.  Lymphoid reconstruction and vaccines.

Authors:  Ronald E Gress; Krishna V Komanduri; Hermann Einsele; Laurence J N Cooper
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

5.  Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.

Authors:  Lawrence G Lum; Mayur Ramesh; Archana Thakur; Subhashis Mitra; Abhinav Deol; Joseph P Uberti; Philip E Pellett
Journal:  Biol Blood Marrow Transplant       Date:  2012-02-05       Impact factor: 5.742

Review 6.  Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.

Authors:  D L DiGiusto; L J N Cooper
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

Review 7.  Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

Review 8.  High throughput T epitope mapping and vaccine development.

Authors:  Giuseppina Li Pira; Federico Ivaldi; Paolo Moretti; Fabrizio Manca
Journal:  J Biomed Biotechnol       Date:  2010-06-15

9.  Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications.

Authors:  Shuhong Han; Yuju Huang; Yin Liang; Yuchin Ho; Yichen Wang; Lung-Ji Chang
Journal:  J Hematol Oncol       Date:  2009-08-06       Impact factor: 17.388

10.  Identification of HLA-A*2402-restricted HCMV immediate early-1 (IE-1) epitopes as targets for CD8+ HCMV-specific cytotoxic T lymphocytes.

Authors:  Jong-Baeck Lim; Hyun Ok Kim; Seok Hoon Jeong; Joo Eun Ha; Sunphil Jang; Sang-Guk Lee; Kyungwon Lee; David Stroncek
Journal:  J Transl Med       Date:  2009-08-23       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.